
MEETING AT A GLANCE

AUGUST 24-28





EVENT LOCATIONS

Subspecialty Reviews	Grand Ballroom Lower Concourse
Brazilian Retina & Vitreous Society: Brainstorm in Retina: A Clinical and Surgical Case Discussion	Grand Ballroom Lower Concourse
General Sessions	Grand Ballroom Lower Concourse
Retina Case Conference	Grand Ballroom Lower Concourse
Continental Breakfasts & Breaks	Grand Foyer Lower Concourse
Lunches	Exhibit Hall Lower Concourse
ASRS International Member Reception	Willow Room Mezzanine
Welcome Reception	Hockey Hall of Fame Off-site
Dragon Boat Races	Toronto Sailing and Canoe Club
	Off-site; shuttle transportation provided
Scientific Posters and Exhibits	Exhibit Hall Lower Concourse
Film Festival Kiosks	Vide Lobby Lower Concourse
Paper on Demand (POD) Kiosks	Grand Ballroom Foyer Lower Concourse
Instructional Courses	Vide Lobby Lower Concourse Grand Ballroom Lower Concourse Essex Ballroom Mezzanine Simcoe/Dufferin, Dominion North, Dominion South, Civic North, Civic South Second Floor
Gala Dinner	Liberty Grand off-site; shuttle
Preceded by reception	transportation provided
Umbo Lounge	Muzik Off-site; shuttle transportation provided
Speaker-Ready Room	VIP Room Concourse
PAT Survey Posters	Exhibit Hall adjacent to booth 225
Young Physicians Section (YPS) Symposium and Lunch	Dominion South Second Floor
Women in Retina (WinR) Symposium and Lunch	Dominion South Second Floor

The American Society of Retina Specialists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this live activity for a maximum of 31 AMA PRA Category 1 Credit(s)^M. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information

In accordance with the ACCME's Standards for Commercial Support, ASRS required all individuals controlling the content of this CME activity to disclose any relevant financial relationships with commercial interests. ASRS implemented mechanisms to manage any conflicts of interest. Please see the program booklet (our mobile meeting site) for disclosure information for all planners and teachers of this CME activity.

SATURDAY, AUGUST 24

8-9 AM	Continental breakfast
8:30-10:30 AM	Subspecialty Reviews
	Moderator: Sophie Bakri, MD
8:30-9:50	What's New, Controversial, and Innovative in Glaucoma, (Complex) Cataract, and IOL Surgery, Ike K. Ahmed, MD; Devesh K. Varma, MD
9:50-10:30	Uveitis, Narsing Rao, MD
10:30-10:45 AM	Break
10:45-11:45 AM	Brazilian Retina & Vitreous Society Symposium
	Brainstorm in Retina: A Clinical and Surgical Case Discussion
	Chair: Walter Takahashi, MD
	Moderator: André Gomes, MD, PhD
	Panelists: Marcio Nehemy, MD, PhD; André Maia, MD; Baruch Kuppermann, MD, PhD; William Mieler, MD; Kourous Rezaei, MD
	Case presenters: Eduardo Cunha de Souza, MD; Mauro Goldbaum, MD; Leandro Cabral Zacharias, MD; Magno Ferreira, MD; Nelson Sabrosa, MD; Leonardo Bruno Oliveira, MD
11:45-12:45 PM	Lunch
12:45-12:50 PM	Welcome
12:50-1:05 PM	Trauma
	Moderators: Jay Duker, MD and Amy Schefler, MD
12:50	High-Power Blue Handheld Laser-Induced Maculopathy: The Results of a Collaborative Retina Study Group, J. Fernando Arevalo, MD, FACS
12:54	Artificial Iris for Posttraumaticc Aniridria or Large Iris Coloboma, Cesare Forlini, MD
12:58	Discussion
1:05-1:35 PM	Pharmacology
	Moderators: Jay Duker, MD and Amy Schefler, MD
1:05	The Barriers to Drug Development, Jeffrey Heier, MD
1:13	Changes in Flare Following Intravitreal Injection of Three Different Anti-VEGF Medications, Nneka Brooks, N
1:21	Penetration and Transportation of Intravitreal Bevacizumab and Ranibizumab Into the Optic Nerve of the Fellow Eye, Sophie Bakri, MD
	Bevacizumab and Ranibizumab Into the Optic Nerve
1:29	Bevacizumab and Ranibizumab Into the Optic Nerve of the Fellow Eye, Sophie Bakri, MD
1:29 1:35-2:40 PM	Bevacizumab and Ranibizumab Into the Optic Nerve of the Fellow Eye, Sophie Bakri, MD Discussion

7-10 PM	Welcome Reception—Hockey Hall of Fame (no CME)
	Panelists: Nur Acar, MD Virgilio Morales-Canton, MD David Chow, MD, FRCS(C) Yusuke Oshima, MD, PhD Stanislao Rizzo, MD Gaurav Shah, MD
	Presenters: Charles Gremillion, MD Paul Hahn, MD, PhD Joseph Martel, MD Pear Pongsachareonnont, MD Tidarat Prechanond, MD Jay Stewart, MD Glenn Yiu, MD, PhD
	Moderators: Carl Awh, MD and Kourous Rezaei, MD
4:45-6 PM	Surgical Case Conference
	Katia Taba, MD, PhD Min Kim, MD Peter Liggett, MD Emil Anthony Say, MD Mohamed Haji, MD, FRCS(C) Shree Kurup, MD Ron Adelman, MD, MPH John Chen, MD, FRCS(C) Christina Weng, MD, MBA Bruce Saran, MD Caroline Chee, MBBS, FRCSEd, FRCOph Zofia Michalewska, MD, PhD Paul Bernstein, MD, PhD David Sarraf, MD Colin McCannel, MD
	Moderators: Richard Spaide, MD and William Mieler, MD Presenters:
3-4:45 PM	Medical Case Conference
2:40-3 PM	Break
2:31	Discussion
2:23	Retinal Vasoproliferative Tumors in Patients With Neurofibromatosis in 6 Patients, Jerry Shields, MD
2:15	Fundus Autofluorescence and Primary Vitreoretinal Lymphoma: Is it Clinically Useful?, Lisa Faia, MD
2:07	Choroidal Thickness After Treatment of Uveal Melanoma With Iodine-125 Plaque Brachytherapy, William Mieler, MD
1:59	Discussion
1:51	Results of Pd-103 Plaque Brachytherapy for Small Choroidal Melanoma, Paul Finger, MD, FACS
	Carol Shields, MD

SUNDAY, AUGUST 25

ar rators: Carl Awh, MD and David Chow, MD, FRCS(C) nization of Vitrectomy for Idiopathic Macular Hole, w MacCumber, MD, PhD
and Peel 27g and 25g Vitrectomy Technique in the gement of Traction Retinal Detachments, Berrocal, MD Angle Glaucoma Following Uncomplicated Pars Vitrectomy. Results of the Pan-American porative Study Group, Virgilio Morales-Canton, MD and Approaches to Fine-Needle Aspiration Biopsy Evaluation of Posterior Uveal Malignant oma Treated With 125-lodine Brachytherapy, hy Murray, MD, MBA assion of Filters on Tissue Visualization in retinal Surgery, David Chow, MD, FRCS(C) cular Lens Rescue Via a Novel Scleral on Technique, Jonathan Prenner, MD on Review of Surgical Development for Subretinal histration of Human Umbilical Tissue-Derived Cells D 2476), Michael Samuel, MD ssion ar eators: Carl Awh, MD and David Chow, MD, FRCS(C) hization of Vitrectomy for Idiopathic Macular Hole, and Outcomes in Patients With Macular Pucker and
gement of Traction Retinal Detachments, Berrocal, MD Angle Glaucoma Following Uncomplicated Pars Vitrectomy. Results of the Pan-American corative Study Group, Virgilio Morales-Canton, MD cal Approaches to Fine-Needle Aspiration Biopsy Evaluation of Posterior Uveal Malignant coma Treated With 125-lodine Brachytherapy, hy Murray, MD, MBA ssion of Filters on Tissue Visualization in cretinal Surgery, David Chow, MD, FRCS(C) cular Lens Rescue Via a Novel Scleral con Technique, Jonathan Prenner, MD in Review of Surgical Development for Subretinal histration of Human Umbilical Tissue-Derived Cells D 2476), Michael Samuel, MD ssion ar cretors: Carl Awh, MD and David Chow, MD, FRCS(C) hization of Vitrectomy for Idiopathic Macular Hole, w MacCumber, MD, PhD cal Outcomes in Patients With Macular Pucker and
Vitrectomy. Results of the Pan-American porative Study Group, Virgilio Morales-Canton, MD cal Approaches to Fine-Needle Aspiration Biopsy Evaluation of Posterior Uveal Malignant oma Treated With 125-lodine Brachytherapy, hy Murray, MD, MBA ssion of Filters on Tissue Visualization in retinal Surgery, David Chow, MD, FRCS(C) cular Lens Rescue Via a Novel Scleral on Technique, Jonathan Prenner, MD on Review of Surgical Development for Subretinal histration of Human Umbilical Tissue-Derived Cells D 2476), Michael Samuel, MD ssion ar eators: Carl Awh, MD and David Chow, MD, FRCS(C) nization of Vitrectomy for Idiopathic Macular Hole, and MacCumber, MD, PhD cal Outcomes in Patients With Macular Pucker and
Evaluation of Posterior Uveal Malignant oma Treated With 125-lodine Brachytherapy, hy Murray, MD, MBA ssion of Filters on Tissue Visualization in retinal Surgery, David Chow, MD, FRCS(C) cular Lens Rescue Via a Novel Scleral on Technique, Jonathan Prenner, MD on Review of Surgical Development for Subretinal histration of Human Umbilical Tissue-Derived Cells (2 2476), Michael Samuel, MD ssion ar rators: Carl Awh, MD and David Chow, MD, FRCS(C) hization of Vitrectomy for Idiopathic Macular Hole, and MacCumber, MD, PhD and Outcomes in Patients With Macular Pucker and
of Filters on Tissue Visualization in retinal Surgery, David Chow, MD, FRCS(C) cular Lens Rescue Via a Novel Scleral on Technique, Jonathan Prenner, MD in Review of Surgical Development for Subretinal histration of Human Umbilical Tissue-Derived Cells D 2476), Michael Samuel, MD ission ar retors: Carl Awh, MD and David Chow, MD, FRCS(C) hization of Vitrectomy for Idiopathic Macular Hole, and MacCumber, MD, PhD ital Outcomes in Patients With Macular Pucker and
cular Lens Rescue Via a Novel Scleral on Technique, Jonathan Prenner, MD on Review of Surgical Development for Subretinal nistration of Human Umbilical Tissue-Derived Cells D 2476), Michael Samuel, MD ossion ar cators: Carl Awh, MD and David Chow, MD, FRCS(C) nization of Vitrectomy for Idiopathic Macular Hole, and MacCumber, MD, PhD cal Outcomes in Patients With Macular Pucker and
on Technique, Jonathan Prenner, MD In Review of Surgical Development for Subretinal histration of Human Umbilical Tissue-Derived Cells D 2476), Michael Samuel, MD ssion ar Pators: Carl Awh, MD and David Chow, MD, FRCS(C) hization of Vitrectomy for Idiopathic Macular Hole, and MacCumber, MD, PhD and Outcomes in Patients With Macular Pucker and
nistration of Human Umbilical Tissue-Derived Cells D 2476), Michael Samuel, MD ssion ar eators: Carl Awh, MD and David Chow, MD, FRCS(C) nization of Vitrectomy for Idiopathic Macular Hole, aw MacCumber, MD, PhD and Outcomes in Patients With Macular Pucker and
ar Tators: Carl Awh, MD and David Chow, MD, FRCS(C) Tation of Vitrectomy for Idiopathic Macular Hole, TW MacCumber, MD, PhD Tatle Outcomes in Patients With Macular Pucker and
rators: Carl Awh, MD and David Chow, MD, FRCS(C) nization of Vitrectomy for Idiopathic Macular Hole, w MacCumber, MD, PhD cal Outcomes in Patients With Macular Pucker and
nization of Vitrectomy for Idiopathic Macular Hole, tw MacCumber, MD, PhD cal Outcomes in Patients With Macular Pucker and
w MacCumber, MD, PhD al Outcomes in Patients With Macular Pucker and
rane Peeling, Gayatri Reilly, MD
linical Course of Vitreofoveal Adhesion Managed tial Observation, Harry Flynn, MD
ssion
ne Features Predictive of Pharmacologic macular Adhesion (VMA) Resolution and nickness Macular Hole (FTMH) Closure Ocriplasmin, Tarek Hassan, MD
cterization of Full-Thickness Macular Holes in the RUST Program: An Optical Coherence graphy (OCT) Analysis of Ocriplasmin Efficacy, Kaiser, MD
asmin for the Treatment of Vitreomacular Traction al Indications and Predictors of Success, I Roth, MD
lar Lucency and Delayed Structural Recovery Macular Hole Closure in the Ocriplasmin III Program, Tamer Mahmoud, MD, PhD
Term Efficacy and Safety of a Single Intravitreal on of Ocriplasmin in Patients With Symptomatic
macular Adhesion (VMA), Jacob Meyer, MD

9:50-11:05 AM	Awards Ceremony	2:10-3:30 PM	AMD 2
	Moderators: John Thompson, MD and Tarek Hassan, MD		Moderators: Jeffrey Heier, MD and Pravin Dugel, MD
9:50 9:55	Pyron Award Introduction, John Thompson , MD Pyron Award, George A. Williams , MD	2:10	Anti-VEGF Therapy Outcomes of First and Second Eyes Utilizing Electronic Medical Records: The Future for Phase IV Trials, Adnan Tufail, MBBS, MD, FRCOphtl
	Pharmacologic Vitreolysis: Past, Present, and Future	2:18	Vitreous Proteomics Reveals a Biomarker Panel That
10:25 10:30	Founders Award Introduction, Tarek Hassan, MD Founders Award, Trexler Topping, MD	2.10	Predicts the Response of Patients With Wet AMD to Treat-and-Extend Therapy, Bert Glaser, MD
11	The Practice of Medicine—Playing by the Numbers Young Physicians Section (YPS), Crystal Apple Award	2:26	Comparison of Systemic Pharmacokinetics Post- Anti-VEGF Intravitreal Injections of Ranibizumab, Bevacizumab and Aflibercept, Robert Avery, MD
11:05-11:50 AM	Genetics and Disease Symposium	2:34	VEGF Plasma Level After Intravitreal Injection of Bevacizumab, Ranibizumab and Pegaptanib in Patient
	Moderators: John Thompson, MD and Tarek Hassan, MD		With Age-Related Macular Degeneration and Diabetic Macular Edema, Gerhard Kieselbach , MD , Prof .
11:05	Genetic Analysis Increases the Predictive Accuracy for Progression From Early to Advanced AMD,	2:42	Discussion
	Lawrence Singerman, MD	2:50	Omega-3 Supplementation and VEGF Levels in
11:13	Earlier Detection of Advanced AMD Due to Office-Based Genetic Testing for AMD Risk,		Wet AMD, Flavio Rezende, MD, PhD
	Peter Sonkin, MD	2:58	Lutein/Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. Results of the
11:21	Genotype Analysis for Single Nucleotide Polymorphisms: Profile of Eyes With Vascularized PED		Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial, Emily Chew, MD
	Due to AMD vs. Eyes Without AMD and Eyes With Drusen, Clement Chan, MD, FACS	3:06	ForeseeHome in AREDS2-Home Monitoring of AMD Patients for Neovascular AMD: Study Design,
11:29	CFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and Zinc in Patients With Age-Related Macular Degeneration Carl Awh, MD		Enrollment, Baseline Characteristics and Initial Device Usage, Susan Bressler, MD
11:37	Discussion	3:14	Periodontal Disease and Age-Related Macular Degeneration, Jorge Arroyo, MD, MPH
		3:18	Discussion
11:50 AM-1:20 PM	General Lunch; Young Physicians Section (YPS) Symposium Lunch (no CME)	3:30-3:50 PM	Break
1:20-2:10 PM	AMD I		
	Moderators: Jeffrey Heier, MD and Pravin Dugel, MD	3:50-5:30 PM	Inherited, Inflammatory, and Infectious Disease
1:20	HARBOR 2-Year Results Support Individualized Dosing in Patients With Wet Age-Related Macular	3:50	Moderators: Harry Flynn, MD and Allen Ho, MD Programed Necrosis, but Not Apoptosis, Mediates
	Degeneration, Brandon Busbee, MD		Photoreceptor Cell Loss and Inflammation in
1:28	Degeneration, Brandon Busbee , MD Effect of Monthly vs PRN Ranibizumab on Patient-Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months,	3:58	Photoreceptor Cell Loss and Inflammation in dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD
	Degeneration, Brandon Busbee , MD Effect of Monthly vs PRN Ranibizumab on Patient-Reported Visual Function for Subfoveal Neovascular	3:58 4:06	dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid,
1:28 1:36 1:40	Degeneration, Brandon Busbee , MD Effect of Monthly vs PRN Ranibizumab on Patient-Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months, Neil Bressler, MD Anti-therapeutic Antibody Status Does Not Appear to Impact Treatment Response to Ranibizumab in the		dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Chronic Central Serous Chorioretinopathy (CSC) Retrospective Study,
:36	Degeneration, Brandon Busbee, MD Effect of Monthly vs PRN Ranibizumab on Patient-Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months, Neil Bressler, MD Anti-therapeutic Antibody Status Does Not Appear to Impact Treatment Response to Ranibizumab in the HARBOR Study, Karl Csaky, MD, PhD Evaluation of the Presence and Extent of Geographic Atrophy Over 2 Years in the HARBOR Trial, SriniVas Sadda, MD Ranibizumab Leads to Regression or Elimination of	4:06	dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Chronic Central Serous Chorioretinopathy (CSC) Retrospective Study, Jennifer Lim, MD Micropulse Photocoagulation Versus Half-Dose Verteporfin Photodynamic Therapy in the Treatment
:36	Degeneration, Brandon Busbee, MD Effect of Monthly vs PRN Ranibizumab on Patient- Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months, Neil Bressler, MD Anti-therapeutic Antibody Status Does Not Appear to Impact Treatment Response to Ranibizumab in the HARBOR Study, Karl Csaky, MD, PhD Evaluation of the Presence and Extent of Geographic Atrophy Over 2 Years in the HARBOR Trial, SriniVas Sadda, MD	4:06 4:14	dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Chronic Central Serous Chorioretinopathy (CSC) Retrospective Study, Jennifer Lim, MD Micropulse Photocoagulation Versus Half-Dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy, Michael Koss, MD Discussion Suprachoroidal Drug Delivery of Triamcinolone
::36	Degeneration, Brandon Busbee, MD Effect of Monthly vs PRN Ranibizumab on Patient-Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months, Neil Bressler, MD Anti-therapeutic Antibody Status Does Not Appear to Impact Treatment Response to Ranibizumab in the HARBOR Study, Karl Csaky, MD, PhD Evaluation of the Presence and Extent of Geographic Atrophy Over 2 Years in the HARBOR Trial, SriniVas Sadda, MD Ranibizumab Leads to Regression or Elimination of Choroidal Neovascular Membranes in Most Eyes With	4:06 4:14 4:22	dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Chronic Central Serous Chorioretinopathy (CSC) Retrospective Study, Jennifer Lim, MD Micropulse Photocoagulation Versus Half-Dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy, Michael Koss, MD Discussion
::36 ::40 ::44	Degeneration, Brandon Busbee, MD Effect of Monthly vs PRN Ranibizumab on Patient-Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months, Neil Bressler, MD Anti-therapeutic Antibody Status Does Not Appear to Impact Treatment Response to Ranibizumab in the HARBOR Study, Karl Csaky, MD, PhD Evaluation of the Presence and Extent of Geographic Atrophy Over 2 Years in the HARBOR Trial, SriniVas Sadda, MD Ranibizumab Leads to Regression or Elimination of Choroidal Neovascular Membranes in Most Eyes With AMD: A HARBOR Subanalysis, John Kitchens, MD	4:06 4:14 4:22	dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Chronic Central Serous Chorioretinopathy (CSC) Retrospective Study, Jennifer Lim, MD Micropulse Photocoagulation Versus Half-Dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy, Michael Koss, MD Discussion Suprachoroidal Drug Delivery of Triamcinolone Acetonide in Vogt-Koyanagi-Harada Disease, Michael J. Davis, MD New Perspectives on Autoimmune Retinopathy: Cases From a National Cancer Institute Designated
1:36	Degeneration, Brandon Busbee, MD Effect of Monthly vs PRN Ranibizumab on Patient- Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months, Neil Bressler, MD Anti-therapeutic Antibody Status Does Not Appear to Impact Treatment Response to Ranibizumab in the HARBOR Study, Karl Csaky, MD, PhD Evaluation of the Presence and Extent of Geographic Atrophy Over 2 Years in the HARBOR Trial, SriniVas Sadda, MD Ranibizumab Leads to Regression or Elimination of Choroidal Neovascular Membranes in Most Eyes With AMD: A HARBOR Subanalysis, John Kitchens, MD Discussion The Effect of Early, Persistent Fluid on Subsequent Visual Acuity in the VIEW 1 and VIEW 2 Studies of	4:06 4:14 4:22 4:28	dsRNA-Induced Retinal Degeneration, Joan Miller, MD Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Chronic Central Serous Chorioretinopathy (CSC) Retrospective Study, Jennifer Lim, MD Micropulse Photocoagulation Versus Half-Dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy, Michael Koss, MD Discussion Suprachoroidal Drug Delivery of Triamcinolone Acetonide in Vogt-Koyanagi-Harada Disease, Michael J. Davis, MD New Perspectives on Autoimmune Retinopathy:

Dragon Boat Races (no CME)
Scientific Posters and Exhibit Hall Reception (no CME)
Discussion
A Cluster of Sterile Inflammation Associated With Aflibercept Intravitreal Injections—An ASRS Therapeutic Surveillance Committee Report, Paul Hahn, MD, PhD
Sterile Intraocular Inflammation in a Cluster of Patients Receiving Intravitreal Injections of Bevacizumab Prepared From a Single Vial, Michael Stewart, MD
Characterization of Sterile Intraocular Inflammatory Reactions After Intravitreal Aflibercept Injection, Deborah Chong, MD
Initial Presentation of Fungal Endophthalmitis Outbreak Following Intravitreal Injections of Triamcinolone Contaminated by a Compounding Pharmacy, Kent Small, MD
The Role of Topical Antibiotic Prophylaxis to Prevent Endophthalmitis After Intravitreal Injection, Sunir Garg, MD
Eliminating Antibiotic Prophylaxis for Intravitreous Injections: A Consecutive Series of 18,839 Injections by a Single Surgeon, Abdhish Bhavsar , MD

MONDAY, AUGUST 26

6:30-8 AM	Continental breakfast
7-7:25 AM	ASRS Business Meeting (no CME)
7:25-7:30 AM	PAT Survey Presentation Thomas Stone, MD
7:30-9:30 AM	Retinal Detachment, Instruments/Devices I
	Moderators: John Pollack, MD and Andrew Schachat, MD
7:30	Management of Retinal Detachments: The European Vitreo-Retinal Society Retinal Detachment Study, Ron Adelman, MD, MPH
7:38	Scleral Buckling for Rhegmatogenous Retinal Detachment Using Vitrectomy-Based Visualization Systems and Chandelier Illumination, Manish Nagpal, MD, FRCS (UK)
7:42	Intraoperative Spectral-Domain OCT During Pars Plana Vitrectomy for Macula-Involving Retinal Detachments Sunil Srivastava, MD
7:46	Does Combined Phacovitrectomy for Rhegmatogenous Retinal Detachment (RRD) Modify the Risk of Developing Proliferative Vitreoretinopathy (PVR)?, Rubina Rahman, MBBS, FRCOpth, FRCS
7:50	Giant Retinal Tear (GRT) Detachments: Surgical Strategies and Outcomes, John Pitcher, MD
7:54	Discussion
8:07	Unexplained Visual Loss After Removal of Silicone Oil: Results of the Pan-American Collaborative Retina Study Group (PACORES), Jose Roca, MD

9:30-10 AM	Break
9:20	Discussion
9:16	Handheld Vitreoretinal SMART Microforceps With Active Tremor Reduction, Peter Gehlbach, MD, PhD
9:08	The Subretinal Implant Alpha IMS to Deliver Useful Vision in Photoreceptor Disease, Caroline Chee MBBS, FRCSEd, FRCOph
9	Three-Year Results From the Argus II Clinical Trial Mark Humayun, MD, PhD
8:52	Application of Intraoperative OCT to Ophthalmic Surgery: PIONEER 18-month iOCT Vitreoretinal Results Justis Ehlers, MD
8:44	Discussion
8:40	Smoking Is a Risk Factor for Proliferative Vitreoretinopathy After Traumatic Retinal Detachment Dean Eliott, MD
8:36	Oral Fluoroquinolones and the Incidence of Rhegmatogenous Retinal Detachment and Symptomatic Retinal Breaks: A Population-Based Study, Andrew Barkmeier, MD
8:23	Discussion
8:19	Suprachoroidal Buckling for Retinal Detachment, Ehab El-Rayes, MD, PhD
8:15	Office-Based Sutureless Scleral Buckling, Nikolas London, MD
8:11	Magnetic Tamponade With Nanoparticles for RD Treatment, Mario Saravia , MD

10-11:20 AM	Socioeconomics
	Moderators: Trexler Topping, MD and Michael Trese, MD
10	Activity-Based Costing (ABC)-Measuring the Vital Signs of a Retinal Practice, Mark Nelson, MD, MBA
10:08	Physician Reimbursement for Retinal Surgery: A Survey of Patients' Perceptions and Attitudes, Leo Kim, MD, PhD
10:16	Do-lt-Yourself Sterile Repackaging of Bevacizumab in a Retina Clinic, Geoffrey Emerson, MD, PhD
10:24	Discussion
10:30	The Compounding Pharmacy Quagmire: Is Your Bevacizumab Sterile? John Thompson, MD
10:38	Mandated Tiered Therapy for Age-Related Macular Degeneration Threatens Physician Choice of Treatment, Tarek Hassan, MD
1046	Discussion
10:52	Physician Payment Reform Update, David Parke, MD
11	BIG DATA: A New Era of Improved Quality, Outcomes and Science, William Rich, MD

11:20 AM-12:40 PM Pediatrics

Discussion

11:08

Moderators: Trexler Topping, MD and Michael Trese, MD

11:20 Endoscopic Pars Plana Vitrectomy Following
Penetrating Eye Injuries in Children,
Emil Anthony Say, MD

Digital Imaging to Reduce Visual Impairment in Neonates and Children, Kimberly Drenser, MD Evolution and Treatment of Traction Retinal Detachments Associated With Severe Coats' Disease in Children, Philip Ferrone, MD Clinical Features and Outcomes of Rhegmatogenous Retinal Detachment in the Pediatric Population, Justin Townsend, MD Discussion General Lunch; Women in Retina (WinR) Lunch (no CME) Scientific Posters and Exhibit Hall Reception (no CME) Women in Retina (WinR) Case Conference (no CME)
Digital Imaging to Reduce Visual Impairment in Neonates and Children, Kimberly Drenser, MD Evolution and Treatment of Traction Retinal Detachments Associated With Severe Coats' Disease in Children, Philip Ferrone, MD Clinical Features and Outcomes of Rhegmatogenous Retinal Detachment in the Pediatric Population, Justin Townsend, MD Discussion General Lunch; Women in Retina (WinR) Lunch (no CME)
Digital Imaging to Reduce Visual Impairment in Neonates and Children, Kimberly Drenser, MD Evolution and Treatment of Traction Retinal Detachments Associated With Severe Coats' Disease in Children, Philip Ferrone, MD Clinical Features and Outcomes of Rhegmatogenous Retinal Detachment in the Pediatric Population, Justin Townsend, MD Discussion
Digital Imaging to Reduce Visual Impairment in Neonates and Children, Kimberly Drenser, MD Evolution and Treatment of Traction Retinal Detachments Associated With Severe Coats' Disease in Children, Philip Ferrone, MD Clinical Features and Outcomes of Rhegmatogenous Retinal Detachment in the Pediatric Population, Justin Townsend, MD
Digital Imaging to Reduce Visual Impairment in Neonates and Children, Kimberly Drenser, MD Evolution and Treatment of Traction Retinal Detachments Associated With Severe Coats' Disease in Children, Philip Ferrone, MD Clinical Features and Outcomes of Rhegmatogenous Retinal Detachment in the Pediatric Population,
Digital Imaging to Reduce Visual Impairment in Neonates and Children, Kimberly Drenser, MD Evolution and Treatment of Traction Retinal Detachments Associated With Severe Coats' Disease
Digital Imaging to Reduce Visual Impairment in
recinopatily of Frematarity, ver em vva, Fib, Fib
Choroidal Thickness in Patients With a History of Retinopathy of Prematurity, Wei-Chi Wu, MD, PhD
Discussion
ROPER: Is It ROP or Is It FEVR?, Audina Berrocal, MD, FACS
Retinal Vascularization After Intravitreal Bevacizumab Injection for Aggressive Posterior Retinopathy of Prematurity (AP-ROP), Sjakon Tahija, MD
Long-term Anatomic, Visual, and Quality-of-Life Outcomes of Lens-Sparing Vitrectomy for Stage 4 Retinopathy of Prematurity, G. Baker Hubbard, MD
Long-term Outcomes of Lens Clarity Following Lens-Sparing Vitrectomy for Retinopathy of Prematurity, Michael Trese, MD
Discussion
Adult Retinopathy of Prematurity: A 35-Year Review, Joshua Robinson, MD
Macular Development In Vivo Followed by Fluorescein Angiography and Spectral-Domain OCT in Premature Patients With Retinopathy of Prematurity (ROP), Maria Martinez-Castellanos, MD

TUESDAY, AUGUST 27

7-8 AM	Continental breakfast	
7:30-9:30 AM	AMD 3, Diabetic Retinopathy I	
	Moderators: Suber Huang, MD, MBA and George Williams, MD	
7:30	Pachychoroid Pigment Epitheliopathy, K. Bailey Freund, MD	
7:38	Cell Therapy for AMD: Interim Results of a Phase 1 Clinical Study Evaluating the Safety and Clinical Response of Human Umbilical Tissue-Derived Cells, Allen Ho, MD	
7:46	MAHALO Phase II Study: Safety, Tolerability and Activity of Lampalizumab (Anti-factor D) in Patients With Geographic Atrophy, David Williams, MD, MBA	
7:54	Discussion	
8:04	Smoking and Choroidal Thickness in Patients Over 65 With Placoid Drusen, Early Atrophic Age-Related Macular Degeneration, and Normals, Eric Sigler, MD	

8:08	Correlation Between the Subfoveal Choroidal Thickness and the Severity or the Progression of Dry Age-Related Macular Degeneration, Young HeeYoon, MD
8:12	Discussion
8:18	Wet AMD: What Happens When You Switch Anti-VEGF Agents?
8:20	Aflibercept for Exudative AMD With Persistent Fluid on Ranibizumab and/or Bevacizumab, Hyung Cho, MD
8:23	What Happens When You Switch Wet-AMD Patients to Aflibercept? Theodore Leng, MD, MS
8:26	Response of Aflibercept in Patients With Neovascular AMD and Persistent Fluid on OCT, Ashish Sharma, MD, FACS
8:29	Longer-term Results of Aflibercept in Cases of Neovascular AMD Incompletely Responsive to Other Anti-VEGF Agents, Franco Recchia , MD
8:32	Long-term Follow-up on the Use of Aflibercept for the Treatment of Refractory Neovascular Age-Related Macular Degeneration, Sara Haug, MD, PhD
8:35	Worsening of Macular Edema After Aflibercept Injection for Exudative ARMD in Eyes Previously Well Controlled With Ranibizumab, Eric Nudleman, MD, PhD
8:38	Discussion
8:48	Intravitreal Ranibizumab Modifies the Natural History of Diabetic Retinopathy: 36-Month Data From the RISE and RIDE Phase III Trials, W. Lloyd Clark, MD
8:56	Effect of Ranibizumab Injections for Diabetic Macular Edema on Risk of Sustained IOP Elevation or Initiation of Ocular Anti-hypertensive Drugs, Suber Huang, MD, MBA
9:04	Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy, Victor Gonzalez, MD
9:12	Discussion
9:20	Evaluation of Nepafenac 0.1% in the Prevention of Macular Edema (ME) Following Cataract Surgery in Patients with Diabetic Retinopathy, Rishi Singh, MD
9:28	Discussion
-	

9:30-10 AM	Break
10-11 AM	Retinal Vascular Disease
	Moderators: David Williams, MD, MBA and Timothy Murray, MD, MBA
10	Effect of Alternate Ranibizumab (RBZ) Dosing Regimens on Visual and Anatomic Outcomes in Patients with Retinal Vein Occlusion (RVO) — The SHORE Study, Dennis Marcus, MD
10:08	Systemic Safety Profile of Intravitreal Ranibizumab in Wet AMD, RVO, and DME: A Meta-Analysis of 14 Phase II/III Clinical Trials, Baruch Kuppermann, MD, PhD
10:16	Factors Associated With the Number of Intravitreal Aflibercept Injections (IAI) During the PRN Phase of CRVO Studies, David Boyer, MD
10:24	Discussion
10:32	Ranibizumab and Aflibercept for the Treatment of Retinal Vein Occlusion (RVO): A Cross-Trial Comparison

Pravin Dugel, MD

12:27-1:30 PM	Lunch
12:20	Optic Nerve Vitrectomy Evaluation (PROVE) Study: A Controlled Clinical Trial, Rohan Shah, MD Discussion
12:12 12:16	Collateral Damage, Kourous Rezaei, MD One-Year Results of the Prospective Retinal and
12:08	latrogenic Retinal Breaks in 25-Gauge Vitrectomy Under Air (Airbag-Vitrectomy) Compared With the Standard 25-Gauge System for Macular Diseases, Cesare Mariotti, MD
12:04	Experimental Comparison of Peripheral Vitreous Incarceration Using Valved and Non-valved Cannula in a Cadaveric Animal Eye Model, Martin Charles, MD
11:54	Discussion
11:50	Vitrectomy With 25-Gauge and Incomplete Drainage of Subretinal Fluid for the Treatment of Primary Rhegmatogenous Retinal Detachment, Stratos Gotzaridis, MBBS, MD
11:46	Retinal and Intravitreal Temperature During Vitreous Surgery, Gabriela Lopezcarasa Hernandez, MD
11:42	Intramacular, Microdissection for Recurrent Macular Holes With Cystic Edges, Nabil Jabbour, MD, FACS
11:38	Optic Pit Maculopathy: Surgical Technique and Long-term Follow-up. A Multicenter Milan Study, Fabio Patelli, MD
11:34	Combined Pars Plana Vitrectomy and Glaucoma Drainage Device Surgery in Complex Pediatric Glaucoma: Outcomes and Complications, Prithvi Mruthyunjaya, MD
11:24	Discussion
11:16	New Shapes for Vitreous Cutter Blades: A Particle Image Velocimetry Study, Tommaso Rossi, MD, EBOD
11:08	Assessment of a New Light-Emitting Diode-Based Light Source for Vitrectomy Surgery, Colin McCannel, MD
11	Expanded Criteria for Pneumatic Retinopexy and Potential Cost Savings, Darin Goldman, MD
	Moderators: David Williams, MD, MBA and Timothy Murray, MD, MBA
11 AM-12:27 PM	Instruments/Devices II, Surgical Techniques II
10:52	Discussion
10:48	Does Addition of Laser Increase Efficacy in Retinal Vein Occlusion Eyes Treated With Simultaneous Bevacizumab and Dexamethasone Intravitreal Implant? Alay Banker, MD
10:44	Safety and Feasibility of a Biodegradable Implant of Dexamethasone (DDS-25 Gauge) for Macular Edema Associated With Retinal Vein Occlusion: A Phase I/II Clinical Trial, Rodrigo Jorge, MD
10:40	Retrospective Study of Two or More Dexamethasone Intravitreal Implant Injections for Treatment of Macular Edema Secondary to Retinal Vein Occlusion, Shree Kurup, MD
10:36	Dexamethasone Implant Anterior-Chamber Migration: Risk Factors, Complications, and Management Strategies, Rahul Khurana , MD

1:30-5:30 PM	Instructional Courses
1:30-2:20 Essex Mezzanine	Duke Surgery Rounds: Deconstructing PPV From A to Z, Paul Hahn, MD, PhD Faculty: Tamer H. Mahmoud, MD, PhD; Prithvi Mruthyunjaya, MD; Glenn J. Jaffe, MD; Carl C. Awh, MD; Dean Eliott, MD; J. Michael Jumper, MD
1:30-2:20 Simcoe/Dufferin Second Floor	EMR Implementation and Optimization for Retina Rishi Singh, MD Faculty: Sanjay Logani, MD, MBA
1:30-2:20 Dominion North Second Floor	Endoscopic Vitrectomy in Adult and Pediatric Vitreoretinal Diseases, S. Wong, MBBS, FRCSEd(ophth), MRCOphth Faculty: Thomas C. Lee, MD; Allen C. Ho, MD; Victor Hugo Gonzalez, MD; Jeffrey S. Heier, MD
1:30-2:20 Civic South Second Floor	ICG Imaging for the Diagnosis and Management of Exudative Age-Related Macular Degeneration Mark Nelson, MD, MBA
1:30-2:20 Civic North Second Floor	Surgical Management of Complicated Retinal Detachments, Jay Chhablani, MD Faculty: Raja Narayanan, MD; Hemanth Murthy, MBBS, MD; Manish Nagpal, MD, FRCS (UK); Alay S. Banker, MD
1:30-3 Grand Ballroom Lower Concourse	Retinaws: When the Going Gets Tough, the Tough Get Going—Challenging Cases in Vitreoretinal Surgery, Kourous Rezaei, MD Faculty: Jose Garcia Arumi, MD, PhD; Carl Claes; Andre V. Gomes, MD, PhD; Ehab N. El-Rayes, MD, PhD; Stratos V. Gotzaridis, MBBS, MD; Homayoun Tabandeh, MD; John T. Thompson, MD; Young Hee Yoon, MD
1:30-2:20 Dominion South Second Floor	'First 20 Dates With Internal Limiting Membrane (ILM)' Tips on Macular Surgery Techniques for Beginners, Malhar Soni, DO, MS, DNB, FRCS Faculty: Pravin U. Dugel, MD; Gopal Lingam, MS, FRCS Steve T. Charles, MD
2:30-3:20 Simcoe/Dufferin Second Floor	Subthreshold Laser Treatment of Diabetic Macular Edema: Methods to Maximize Structural and Visual Outcomes, Jeffrey Luttrull, MD Faculty: Stephen H. Sinclair, MD; Edoardo Midena, MD, PhD, FARVO, FEBO
2:30-3:20 Dominion South Second Floor	Vitreomacular Interface Pathology: OCT Interpretations, Wai-Ching Lam, MD, FRCS(C) Faculty: Emmanouil Mavrikakis, MD, PhD; Varun Chaudhary, MD; Shao Onn Yong, MD, FRCSE; Rajeev H Muni, MD, MSC, FRCSC
2:30-3:20 Dominion North Second Floor	Powerplay: Vitreoretinal Surgery in Inflamed Eyes, Thomas Albini, MD Faculty: Steven Yeh, MD; Efrem D. Mandelcorn, MD; Rahul N. Khurana, MD
2:30-3:20 Civic North Second Floor	Intraocular Tumors and Pseudotumors. Rapid-Fire Cases and Clinical Pearls, Jerry Shields, MD Faculty: Carol L. Shields, MD
2:30-3:20 Civic South Second Floor	Anterior-Segment Microsurgery for the Vitreoretinal Surgeon: Techniques, Tools, and Tips, Yannek Leiderman, MD, PhD Faculty: Maria H. Berrocal, MD; Netan Choudhry, MD, FRCS(C); Jonathan L. Prenner, MD

2:30-4 Essex Mezzanine	ASRS Research and Therapeutics Committee Symposium: Clinical Trials "Unplugged": Real, Practical Questions and Answers, Pravin Dugel, MD Faculty: David M. Brown, MD; Allen C. Ho, MD; David S. Boyer, MD; Michael A. Singer, MD; Donald J. D'Amico, MD; Baruch Kuppermann, MD, PhD; John Kitchens, MD; J. Michael Jumper, MD; Robert Avery, MD; Tarek Hassan, MD; William Mieler, MD; Anthony Capone, Jr., MD
3:10-4:40 Grand Ballroom Lower Concourse	Challenge the Masters, Calvin Mein, MD Faculty: Virgilio Morales-Canton, MD; Gabriela Lopezcarasa Hernandez, MD
3:30-4:20 Civic North Second Floor	Combined Phaco-Vitrectomy: Tips and Tricks, Yew San Ian Yeo, MBBS, FRCS Faculty: Doric Wong, MD; Laurence Lim, MBBS, FRCSEd; Boon K. Loh, MBBS, FRCSEd
3:30-4:20 Dominion North Second Floor	Incorporating Compounding Into Your Retinal Practice Abdhish Bhavsar, MD Faculty: Geoffrey G. Emerson, MD, PhD; Jacob M. Jones, MD, PhD
3:30-4:20 Simcoe/Dufferin Second Floor	Scleral Buckling: A Forgotten Art! Gopal Lingam, MS, FRCS, Faculty: Caroline Chee, MBBS, FRCSEd, FRCOph; Malhar Soni, DO, MS, DNB, FRCS; P. Mahesh Shanmugam, DO, FRCSEd, PhD, FAICO(VR)
3:30-4:20 Civic South Second Floor	Uveitis Face-off: Controversies in Uveitis Management, Steven Yeh, MD Faculty: Thomas A. Albini, MD;Howard F. Fine, MD, MHSc; Farzin Forooghian, MD, MSc, FRCS(C); Sunil Srivastava, MD
3:30-4:20 Dominion South Second Floor	Suprachoroidal Space Surgery, Ehab El-Rayes, MD, PhD Faculty: Stanislao Rizzo, MD; Yusuke Oshima, MD, PhD; Virgilio Morales-Canton, MD
4:30-5:20 Simcoe/Dufferin Second Floor	Real-World Retina 101: How to Establish the Type of Career You Want (no CME), Netan Choudhry, MD, FRCS(C) Faculty: Vincent S. Hau, MD, PhD; Yannek I. Leiderman, MD, PhD; Amy Babiuch, MD; Jawad Qureshi, MD, MBA
4:30-5:20 Civic South Second Floor	IOL Rescue: Intrascleral Haptic Fixation, Somdutt Prasad, MS, FRCSEd, FRCOphth, FACS Faculty: Jonathan L. Prenner, MD; Jonathan A. Feistmann, MD; Malhar Soni, DO, MS, DNB, FRCS
4:30-5:20 Essex Mezzanine	Newer Advances in Vitreo-Retina Surgeries: Tools and Techniques, S. Natarajan, MD Faculty: Manish Nagpal, MD, FRCS (UK); Yusuke Oshima, MD, PhD; Ehab N. El-Rayes, MD, PhD; Alay S. Banker, MD
4:30-5:20 Dominion South Second Floor	Pneumatic Retinopexy: Pearls and Pitfalls Peter Kertes, MD, FRCS(C) Faculty: Emmanouil Mavrikakis, MD, PhD; Rajeev H Muni, MD, MSC, FRCS(C); Stephen M. Conti, MD; Varun Chaudhary, MD
4:30-5:20 Dominion North Second Floor	A Genetic Approach to Inherited Retinal Dystrophies: Updates on Clinical Classification of Common Retinal Dystrophies, Genotyping, and Gene Therapy, Christine Kay, MD
7-9 PM	Gala Reception & Dinner Board busses at 6:30 from Richmond Street
9 PM-12 midnight	Umbo Lounge at Nightclub Muzik Immediately following dinner

WEDNESDAY, AUGUST 28

7:30-8:30 AM	Continental breakfast
8-8:21 AM	Surgical Techniques III
	Moderators: Donald D'Amico, MD and Virgilio Morales-Canton, MD
8	Lutein: A New Dye for Chromovitrectomy, Mauricio Maia, MD, PhD
8:04	Vitrectomy for Macular Hole Retinal Detachment (MHRD) in High Myopia, Stanislao Rizzo, MD
8:08	25-Gauge Vitrectomy for Macular Holes With and Without Retinal Detachment in Highly Myopic Eyes, Francesco Boscia, MD
8:12	Inverted Internal Limiting Membrane Flap Technique in Macular Hole Associated With Pathological Myopia, Jerzy Nawrocki, MD, PhD
8:16	Discussion
8:21-9:46 AM	Imaging
	Moderators: Donald D'Amico , MD and Virgilio Morales-Canton , MD
8:21	Clinical Feasibility and Utility of Ultra Wide-field Indocyanine Green (ICG) Angiography, Szilard Kiss, MD
8:29	Adaptive Optics Scanning Laser Ophthalmoscope Fluorescein Angiography (AO SLO FA) and Motion Contrast Imaging of Retinal Microaneurysms, Richard Rosen, MD
8:37	Discussion
8:43	Diurnal Variation of Macular Choroidal Volume in Healthy Volunteers, Lihteh Wu, MD
8:51	Two-Year Macular Volume Change of the Retinal Pigment Epithelium and Drusen Complex (RPEDC) in Intermediate AMD by SD-OCT Semi-Automated Segmentation, Thomas Hwang, MD
8:59	Discussion
9:05	Correlation of Precise Area of Peripheral Non-perfusion With the Ischemic Index in Retinal Vein Occlusion, Michael Singer, MD
9:09	Lamina Suprachoroidea and Suprachoroidal Space Delineating the Outer Margin of the Choroid in Swept-Source OCT, ZofiaMichalewska, MD, PhD
9:13	Intraoptic Nerve Head and Retina Silicone Oil Microspherules: OCT (Swept Source) and Adaptive Optics Reflectance Imaging, Yale Fisher, MD
9:17	Can Retro-illuminated Infrared Choroidal Imaging Distinguish Polypoidal Choroidal Vasculopathy From Neovascular Age-Related Macular Degeneration? Christina Leung, MD, FRCS(C)
9:21	Discussion
9:28	SD-OCT and Fundus Autofluorescence Findings of Acute Syphilitic Posterior Placoid Chorioretinopathy: An International Perspective, David Sarraf, MD
9:32	Evaluation of a Combination Non-mydriatic Digital Fundus Camera With Spectral Domain OCT in Telemedicine for the Screening of Diabetic Retinopathy, John Wroblewski, MD

9:36	Enhanced Depth Imaging Optical Coherence
	Tomography in Patients With Different Phase

Behçet's Disease, Gursel Yilmaz, MD

9:40 Discussion

9:46-10:10 AM Break

10:40-11:50

10:10-10:40 AM Global Trends in Retina

Moderators: Lihteh Wu, MD and Francesco Boscia, MD

Moderator:

Malhar Soni, DO, MS, DNB, FRCS

Europe & Asia: 'Retina Practice Trends'

Panelists:

Martin Charles, MD South America

Ehab El Rayes, MD, PhD Middle East & Africa

Kourous Rezaei, MD North America: ASRS PAT Survey

Stanislao Rizzo, MD Europe

Diabetic Retinopathy II

P. Mahesh Shanmugam, DO, Asia: 'Retina

FRCSEd, PhD, FAICO(VR) Practice Trends'

	Moderators: Lihteh Wu, MD and Francesco Boscia, MD
10:40	Why the 0.3 mg Dose of Ranibizumab Was Recommended for the Treatment of Diabetic Macular Edema, Donald D'Amico, MD
10:48	Residual Edema Evaluation With 0.5 mg and 2.0 mg Ranibizumab Formulations (REEF Study), Dilsher Dhoot, MD
10:56	Discussion
11:02	A Prospective Study of Anterior-Chamber Cytokine Levels and Their Association With Disease Severity in Diabetic Macular Edema, David Wong, MD, FRCS(C)
11:10	Anterior Chamber Cytokine Level Changes in Diabetic Macular Edema After Treatment With Intravitreal Ranibizumab, Rajeev Muni, MD, MSC, FRCS(C)
11:18	The Role of Macular Ischemia in Treatment-Naive Patients With Diabetic Macular Edema Treated With Intravitreal Ranibizumab Only, Andreas Ebneter, MD, PhD
11:22	A 12-Month, Masked, Randomized Controlled Study to Assess Efficacy of Dexamethasone Intravitreal Implant and Bevacizumab Compared With Bevacizumab Alone for Diabetic Macular Edema, Raj Maturi, MD
11:26	Discussion
11:36	Safety of Transfoveal Subthreshold Diode Micropulse Laser (TF SDM) for Intrafoveal Diabetic Macular Edema (IF DME) in Eyes With Good Visual Acuity, Jeffrey Luttrull, MD
11:40	Combination of Anti-angiogenic Therapy and Navigated Laser for the Treatment of Diabetic Macular Edema (DME): 12-Month Results, Igor Kozak, MD, PhD

Discussion

11:44